What We Do
Building Our Portfolio
Incanthera has a unique and valuable research base through its pipeline deal with the Insititute of Cancer Therapeutics. This provides a continuing source of high quality drug development opportunities (potentially one per year) in oncology.
In addition, the company has, in its short history, identified and added new drugs to its development portfolio, through acquisition of two life science companies (Onco NX and Spear Therapeutics).
We believe that there is a real opportunity to build a sustainable commercially focussed, oncology company through a combination of our pipeline deal with the ICT and identification and acquisition of further drug opportunities from a variety of sources, including, Universities, other small research companies and ‘spin-outs’ from major pharmaceutical companies.